Evidence map›Paper›PMID 41427364›Full record

ArticlebioRxiv : the preprint server for biology2026

Efagins - engineerable agents that evolved independently to target the enterococcal cell wall.

Janira Prichula, Abigail L Manson, Joshua T Smith, Natia Karumidze, Gracie Richards, Suelen S Mello, Artur Czajkowski, Mohammed Kaplan, Ashlee M Earl, Michael S Gilmore

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Janira PrichulaDepartment of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-6767-8890
Abigail L MansonInfectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0002-3800-0714
Joshua T SmithInfectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0001-5511-8717
Natia KarumidzeEliava Institute of Bacteriophages, Tbilisi, Georgia.ORCID 0000-0002-3069-7123
Gracie RichardsInfectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0001-7592-4185
Suelen S MelloDepartment of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-6389-6041
Artur CzajkowskiUniversity of Chicago, Chicago, IL, USA.ORCID 0009-0000-8678-5643
Mohammed KaplanUniversity of Chicago, Chicago, IL, USA.ORCID 0000-0002-0759-0459
Ashlee M EarlInfectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0001-7857-9145
Michael S GilmoreDepartment of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-6389-832X

Funding

Viral Genomics: evolution, spread, and host interactionsU19AI110818 · NIAID · BROAD INSTITUTE, INC. · PI NEAFSEY, DANIEL E · 2014 to 2024
$66.5M
Technical Mother Machine CoreP01AI083214 · NIAID · SCHEPENS EYE RESEARCH INSTITUTE · PI Suzanne Walker · 2009 to 2026
$39.4M
In situ investigation of bacterial secretion systems using cryo-electron tomographyR35GM157116 · NIGMS · UNIVERSITY OF CHICAGO · PI MOHAMMED KAPLAN · 2025 to 2026
$820k
Deep integration of multi-omics and patient health data to clarify risk factors of enterococcal infective endocarditisF32AI179151 · NIAID · BROAD INSTITUTE, INC. · PI Joshua Thomas Smith · 2024 to 2026
$160k
NIAID NIH HHS F32 AI179151NIAID NIH HHS P01 AI083214NIAID NIH HHS U19 AI110818NIGMS NIH HHS R35 GM157116
6 · The paper itself

Abstract

Enterococci are major causes of multidrug-resistant infections, and antimicrobials with fundamentally new mechanisms of action are urgently needed. We identify a new class of antibacterial agents, termed efagins, which are chromosomally encoded, phage-related nanomachines that recognize cell wall carbohydrate receptors and inhibit subsets of

Indexed as

antimicrobial agentsefaginEnterococcus faecalisEnterococcus faeciumEpageneralist specieshospital acquired infectionphage-related elementsRha-CWPSVRE

Identifiers

PMID41427364
PMCPMC12713668

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.